Sign In
Buy ATNM
$1.11
-0.0500 (-4.31%)
At Close: Jun 04, 2026
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc.
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Ph
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of inv
NEW YORK CITY, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actin
NEW YORK CITY, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATN
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)
11:57am, Friday, 28'th Mar 2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of
ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). The lawsuit al
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:00pm, Thursday, 27'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)--ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
06:07pm, Thursday, 27'th Mar 2025
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the Un
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in heal
- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - �
NEW YORK , March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it
NEW YORK , March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
08:30am, Wednesday, 19'th Mar 2025
- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - Clinical
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs – Myeloid Derived Supp
